Clinical Research | Novartis

Press Release
Aug 12, 2025

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Press Release
Feb 28, 2025

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
Story
May 31, 2024

A legacy of blood cancer innovation
Press Release
Dec 11, 2023

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
Story
Dec 21, 2022

Compassionate use: Providing access to much needed treatments
Story
Jun 23, 2022

Renewing our commitment to neglected tropical disease and malaria elimination
Story
Dec 06, 2021

When it comes to cancer, there’s power in a good partner
Story
Nov 23, 2020

New hope for treating inflammatory diseases of the kidney
Story
Jul 09, 2020

Cancer didn’t stop for COVID-19
Story
May 12, 2020

Moving from speculation to science during a pandemic
Press Release
Apr 22, 2020

Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
Story
Apr 20, 2020

Going the extra mile to keep clinical trials on track during the COVID-19 pandemic